Tolerability and Positive Efficacy Results after Subcutaneous Immunotherapy with Parietaria Judaica Depot Extract

Abstract

Aim: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. Patients & methods: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. Results: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score. Conclusion: P. judaica subcutaneous immunotherapy (Allergovac® depot ROXALL Medicina España S.A., Zamudio, Spain) with an abbreviated up-dosing scheme showed an adequate safety and tolerability profile and induced preliminary efficacy changes.

Parietaria Allergy: An Intriguing Challenge for the Allergist

“…Another interesting aspect is the tolerability of SCIT: a very recent study demonstrated that Parietaria judaica subcutaneous immunotherapy (Allergovac ® depot ROXALL Medicina España), with an abbreviated up-dosing scheme, showed an adequate safety and tolerability profile and induced preliminary efficacy changes [53]. This indicates that a rapid schedule may be safe and well tolerated.…”